ITCMDBv1
Clinical TrialID 8363

Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression

NCT06094907

Depressive Disorder|Depression, Unipolar

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
8363
Evidence Id
8363
Core Evidence Id
8363
Source Clinical Trial Id
8361
Herb2 Clinical Trial Id
HBCT008361
Nct Id
NCT06094907
Title
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
Status
Completed
Phase
Phase 2
Study Result
No
Study Condition
Depressive Disorder|Depression, Unipolar
Study Type
Interventional
Study Design
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
Intervention
DRUG: N,N-Dimethyltryptamine
Intervention Allocation
Intervention Model
Single_Group
Intervention Mask
Intervention Purpose
Treatment
Gender
All
Age
Adult
Enrollment
14
Outcome Measure
Change in MADRS scores, Change in MADRS scores from baseline to 7 days after the dosing session. The Montgomery and Asberg Depression Rating Scale (MADRS) is in portuguese and has 10 items, with an overall score ranging from 0 to 60 points. Higher score indicates more severe depression., 7 days
Sponsor Collaborator
Universidade Federal do Rio Grande do Norte
Funded By
OTHER
Location
Hospital Universitário Onofre Lopes, Natal, RN, 59012300, Brazil
Other Id
DMTPRD
Start Date
2023-10-09
Primary Completion Date
2024-01-15
Completion Date
2024-03-30
First Posted
2023-10-23
Results First Posted
Last Update Posted
2024-05-08
Study Document
Study Url
https://clinicaltrials.gov/study/NCT06094907
Title Cn
Title En
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
Bilingual Status
semi_complete